SeaStar Medical Holding (ICU) said Monday that the US Food and Drug Administration has approved its investigational device exemption application, allowing the conduct of a study to evaluate the safety and initial efficacy of its selective cytopheretic device, or SCD-Adult, in cardiorenal syndrome.
The device will be evaluated in adults with acute heart failure and worsening renal function or severe right ventricular failure awaiting left ventricular assist device implantation, according to SeaStar Medical.
The study is expected to include 20 patients at up to five clinical sites and is funded by a $3.6 million grant from the National Institutes of Health, SeaStar said.
Shares of the company were 3% lower in early trading Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。